Abstract
A multicenter, double-blind, randomized, placebo-controlled trial was conducted to assess the effects of verapamil on total mortality, cardiac mortality, reinfarction, and angina after an acute myocardial infarction. All patients, aged 30 to 75 years, consecutively admitted for acute myocardial infarction between 1985 and 1987 to the participating centers, and without contraindications to verapamil or history of severe heart failure were enrolled. Seven to 21 days (mean 13.8) after myocardial infarction, 531 patients were randomized to verapamil retard 360 mg/day, and 542 patients to placebo. At baseline, the 2 groups of patients had similar characteristics. Mean age was 55.5 years and 91% were men. During a mean follow-up of 23.5 months, 5.5% of the patients died. No differences between verapamil and placebo were observed in total mortality (n = 30 and 29, respectively) and cardiac death (n = 21 and 22, respectively). The verapamil group had nonsignificant lower reinfarction rates (n = 39 vs 49). The number of patients developing angina was significantly less in the verapamil group (n = 100 vs 132, RR = 0.8, 95% confidence interval 0.5 to 0.9). There were no differences in discontinuation of therapy caused by adverse reactions. This trial showed no effect of verapamil on mortality. The lower reinfarction rates found in the verapamil group are in agreement with the results of other studies.
| Original language | English |
|---|---|
| Pages (from-to) | 365-369 |
| Number of pages | 5 |
| Journal | The American Journal of Cardiology |
| Volume | 77 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Feb 15 1996 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
A controlled trial of verapamil in patients after acute myocardial infarction : Results of the Calcium Antagonist Reinfarction Italian Study (CRIS). / Rengo, Franco; Carbonin, Pierugo; Pahor, Marco; De Caprio, Lorenzo; Bernabei, Roberto; Ferrara, Nicola; Carosella, Luciana; Acanfora, Domenico; Parlati, Stefania; Vitale, Dino.
In: The American Journal of Cardiology, Vol. 77, No. 5, 15.02.1996, p. 365-369.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A controlled trial of verapamil in patients after acute myocardial infarction
T2 - Results of the Calcium Antagonist Reinfarction Italian Study (CRIS)
AU - Rengo, Franco
AU - Carbonin, Pierugo
AU - Pahor, Marco
AU - De Caprio, Lorenzo
AU - Bernabei, Roberto
AU - Ferrara, Nicola
AU - Carosella, Luciana
AU - Acanfora, Domenico
AU - Parlati, Stefania
AU - Vitale, Dino
PY - 1996/2/15
Y1 - 1996/2/15
N2 - A multicenter, double-blind, randomized, placebo-controlled trial was conducted to assess the effects of verapamil on total mortality, cardiac mortality, reinfarction, and angina after an acute myocardial infarction. All patients, aged 30 to 75 years, consecutively admitted for acute myocardial infarction between 1985 and 1987 to the participating centers, and without contraindications to verapamil or history of severe heart failure were enrolled. Seven to 21 days (mean 13.8) after myocardial infarction, 531 patients were randomized to verapamil retard 360 mg/day, and 542 patients to placebo. At baseline, the 2 groups of patients had similar characteristics. Mean age was 55.5 years and 91% were men. During a mean follow-up of 23.5 months, 5.5% of the patients died. No differences between verapamil and placebo were observed in total mortality (n = 30 and 29, respectively) and cardiac death (n = 21 and 22, respectively). The verapamil group had nonsignificant lower reinfarction rates (n = 39 vs 49). The number of patients developing angina was significantly less in the verapamil group (n = 100 vs 132, RR = 0.8, 95% confidence interval 0.5 to 0.9). There were no differences in discontinuation of therapy caused by adverse reactions. This trial showed no effect of verapamil on mortality. The lower reinfarction rates found in the verapamil group are in agreement with the results of other studies.
AB - A multicenter, double-blind, randomized, placebo-controlled trial was conducted to assess the effects of verapamil on total mortality, cardiac mortality, reinfarction, and angina after an acute myocardial infarction. All patients, aged 30 to 75 years, consecutively admitted for acute myocardial infarction between 1985 and 1987 to the participating centers, and without contraindications to verapamil or history of severe heart failure were enrolled. Seven to 21 days (mean 13.8) after myocardial infarction, 531 patients were randomized to verapamil retard 360 mg/day, and 542 patients to placebo. At baseline, the 2 groups of patients had similar characteristics. Mean age was 55.5 years and 91% were men. During a mean follow-up of 23.5 months, 5.5% of the patients died. No differences between verapamil and placebo were observed in total mortality (n = 30 and 29, respectively) and cardiac death (n = 21 and 22, respectively). The verapamil group had nonsignificant lower reinfarction rates (n = 39 vs 49). The number of patients developing angina was significantly less in the verapamil group (n = 100 vs 132, RR = 0.8, 95% confidence interval 0.5 to 0.9). There were no differences in discontinuation of therapy caused by adverse reactions. This trial showed no effect of verapamil on mortality. The lower reinfarction rates found in the verapamil group are in agreement with the results of other studies.
UR - http://www.scopus.com/inward/record.url?scp=9044225950&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9044225950&partnerID=8YFLogxK
U2 - 10.1016/S0002-9149(97)89365-4
DO - 10.1016/S0002-9149(97)89365-4
M3 - Article
C2 - 8602564
AN - SCOPUS:9044225950
VL - 77
SP - 365
EP - 369
JO - American Journal of Cardiology
JF - American Journal of Cardiology
SN - 0002-9149
IS - 5
ER -